Discussions to Focus on the Role of Sleep Innovation for Brain Health and the Influence of the Microbiome on Human Well-being
TOKYO and BOSTON and HERZLIYA, Israel, May 22, 2025 /PRNewswire/ — Corundum Neuroscience (CNS), the neuroscience venture builder and fund, and Corundum Systems Biology (CSB), a leading investor in life-changing systems biology solutions for human health, announced today that they will host panel sessions at the inaugural SXSW London, taking place June 2-7, 2025.
Moderated by Jessica Schneider, PhD, Chief Scientific Officer at Corundum Systems Biology, panelists will explore how the human microbiome – the body’s complex ecosystem of microorganisms – is becoming a foundation of precision medicine. They will discuss the role of the microbiome as a critical mediator between our bodies and what we consume, and how new research is transforming our approach to healthcare. Panelists will discuss how microbiome science is reshaping drug development, nutrition and women’s health, and offering new insights into personalized health interventions.
“This conversation comes at a critical time, as we move from a one-size-fits-all approach to healthcare to personalized solutions for more targeted and effective interventions,” said Dr. Schneider. “I’m excited to bring this conversation to the first ever SXSW London to discuss how pioneering microbiome research is influencing drug development and clinical applications that can reshape wellness strategies.”
Moderated by Ruthi Aladjem, PhD, Chief Product Strategist at Corundum Neuroscience, the session will explore the future of sleep as a platform for discovery. Panelists will discuss how emerging technology is increasing our understanding of brain activity during sleep, highlighting breakthroughs in enhancing cognitive health, enabling early detection of neurodegenerative diseases, and improving human performance. It will explore how innovations in sleep tech are reshaping our understanding of sleep, from a biological function to a vital tool for medical and scientific discovery.
“Sleep is no longer just a passive state of rest, but rapidly emerging as a pivotal frontier for innovation in health and wellbeing,” said Dr. Aladjem. “I’m thrilled to join this panel as we dive into the breakthroughs that are transforming our understanding of the brain and reimagining human potential in a tech-driven age.”
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track-record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people’s health, longevity and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023, and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit: https://cnsfund.com.
About Corundum Systems Biology
Corundum Systems Biology (CSB) is dedicated to advancing breakthroughs in human health and well-being by supporting groundbreaking companies in the field of systems biology. Committed to the long-term success and impact of its portfolio companies, Corundum Systems Biology offers deep domain expertise, connections to a broad network of industry and scientific leaders, and access to unique sources of health data.
For company updates and information, follow Corundum Systems Biology on LinkedIn or visit https://www.csb.co.jp/.
Media Contact:
Danny Sudwarts
FINN Partners for Corundum
danny.sudwarts@finnpartners.com
SOURCE Corundum Neuroscience; Corundum Systems Biology
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…